Cogent Biosciences, Inc.
COGT
Pozycja w akcjach
#3284
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Cena akcji
$31.17
Kapitalizacja rynkowa
$5.41B
Zmiana (1 dzień)
3.87%
Zmiana (1 rok)
92.17%
Kraj
US
Handel Cogent Biosciences, Inc. (COGT)
Kategoria
Healthcare
Wskaźnik P/B dla Cogent Biosciences, Inc. (COGT)
Wskaźnik P/B na dzień October 2026 TTM: 9.04
Według najnowszych raportów finansowych i ceny akcji Cogent Biosciences, Inc., obecny wskaźnik P/B (TTM) wynosi 9.04. Na koniec 2023 wynosił 1.82.
Historia wskaźnika P/B dla Cogent Biosciences, Inc. od 2015 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 9.04 | 186.14% |
| 2024 | 3.16 | 73.98% |
| 2023 | 1.82 | -31.58% |
| 2022 | 2.66 | 71.14% |
| 2021 | 1.55 | 192.57% |
| 2020 | 0.53 | -23.25% |
| 2019 | 0.69 | -62.01% |
| 2018 | 1.82 | -84.34% |
| 2017 | 11.61 | 133.80% |
| 2016 | 4.97 | 32.70% |
| 2015 | 3.74 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | -30.87% |
US
|
|
| 13.2547 | 46.59% |
US
|
|
| 4.208 | -53.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.62% |
NL
|
